2Roguin A, Bomma CS, Nasir K, et al. Implantable cardioverter- defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol, 2004, 43: 1843- 1852.
3Sarkozy A, Boussy T, Kourgiannides G, et al. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J, 2007,28:334-344.
4Wichter T, Paul M, Wollmarm C, et al. Implantable cardioverter/ defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation, 2004, 109:1503- 1508.
5Nademanee K, Veerakul G, Mower M, et al. Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT) : a randomized clinical trial. Circulation, 2003,107:2221-2226.
6Zipes DP, Camm AJ, Borggrefe M, Guidelines for Management of et al. ACC/AHA/ESC 2006 Patients With Ventrieular Arrhythmias and the Prevention of Sudden Cardiac Death : a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) : developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation,2006,114 : e385-e484.
7Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricular taehycardia in hypertrophic cardiomyopathy: independent marker of sudden death risk in young patients. J Am Coll Cardiol,2003 ,42 :873-879.
8Olivotto I, Maron B J, Montereggi A, et al. Prognostic value of systemic blood pressure response during exercise in a community- based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol, 1999,33:2044-2051.
9Adabag AS, Casey SA, Kuskowski MA, et al. Spectrum and prognostic significance of arrhythmias on ambulatory Hoher electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol,2005,45:697-704.
10Maron B J, Casey SA, Poliac LC, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA, 1999,281:650-655.
4Faber L,Welge D,Fassbender D.One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients:predictors of hemodynamic and clinical response[J].Clin Res Cardio,2007,96(12):864-873.
5Van der Lee C,Scholzel B,ten Berg JM,et al.Usefulness of clinical,echocardiographic,and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation[J].Am J Cardiol,2008,97(4):234-243.
6Gersh B J, Maron B J, Bonow RO, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology FoundatiordAmerican Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons [J] J Am Coil Cardiol, 2011, 58(25): e212-e260.
7Bonow RO, Carabello BA, Chatterjee K,et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons [J]. Am Coil Cardiol, 2008, 52(13): e1-142.
8Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction [J]. Circulation, 2006, 114(21): 2232-2239.
9Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive eardiomyopathy [J]. Lancet, 1995, 346(8969): 21 l-214.
10Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systemic review ofpublished studies [J]. J Interven Cardiol, 2006, 19(4): 319-327.
